Compare GSK plc (GSK) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.92 (market cap $1.45B). The key difference: GSK plc is far larger — about 63.4× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and GSK plc pays a 3.9% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days on average.
| GSK | QQQE | |
|---|---|---|
Market Cap | $91.88B | $1.45B |
Volume | 7,730,529 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $124.69 |
52-Week Low | $43.24 | $96.06 |
Typical Hold Time | 93 Days | 48 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
QQQE trades at $121.92 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with moving averages supporting upward momentum while oscillators remain neutral. The ETF's equal-weighted approach to NASDAQ-100 stocks provides diversification benefits, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers stronger fundamentals and technicals than QQQ for tactical positioning.
The outlook appears favorable with equal weighting providing balanced exposure to large-cap growth stocks. Key risks include technology sector volatility and market concentration concerns. Analyst sentiment leans positive for near-term performance, though investors should monitor broader market trends and sector rotations that could impact the NASDAQ-100 composition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
